Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. (Record no. 27109157)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02385 a2200649 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250517151632.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201708s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1474-5488 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1016/S1470-2045(17)30279-6 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Coleman, Robert L |
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Date of production, publication, distribution, manufacture, or copyright notice | 20170824 |
245 00 - TITLE STATEMENT | |
Title | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | The Lancet. Oncology |
Date of publication, distribution, etc. | 06 2017 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 779-791 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Adult |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Aged, 80 and over |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
General subdivision | adverse effects |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Bevacizumab |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carboplatin |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Carcinoma, Ovarian Epithelial |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Cytoreduction Surgical Procedures |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Disease-Free Survival |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Fallopian Tube Neoplasms |
General subdivision | therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Female |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Humans |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Middle Aged |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Neoplasm Recurrence, Local |
General subdivision | therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Neoplasms, Glandular and Epithelial |
General subdivision | therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Ovarian Neoplasms |
General subdivision | therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Paclitaxel |
General subdivision | administration & dosage |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Peritoneal Neoplasms |
General subdivision | therapy |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Survival Rate |
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Young Adult |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Brady, Mark F |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Herzog, Thomas J |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Sabbatini, Paul |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Armstrong, Deborah K |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Walker, Joan L |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kim, Byoung-Gie |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Fujiwara, Keiichi |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Tewari, Krishnansu S |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | O'Malley, David M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Davidson, Susan A |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Rubin, Stephen C |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | DiSilvestro, Paul |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Basen-Engquist, Karen |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Huang, Helen |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Chan, John K |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Spirtos, Nick M |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Ashfaq, Raheela |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Mannel, Robert S |
773 0# - HOST ITEM ENTRY | |
Title | The Lancet. Oncology |
Related parts | vol. 18 |
-- | no. 6 |
-- | p. 779-791 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1016/S1470-2045(17)30279-6">https://doi.org/10.1016/S1470-2045(17)30279-6</a> |
Public note | Available from publisher's website |
No items available.